Numinus Wellness OTCPK:NUMI.F Rapporto sulle azioni Dati finanziari dell'azienda + 1 Analista
Numinus Wellness Inc.
OTCPK:NUMI.F Rapporto sulle azioni
Cap. di mercato: US$12.7m
NUMI.F Panoramica delle azioni Numinus Wellness Inc. fornisce prodotti e servizi di psicoterapia assistita da psichedelici in Canada e negli Stati Uniti.
Informazioni sull'azienda
Premi Analisi del rischio Vedi tutti gli assegni di rischio Numinus Wellness Inc. Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Numinus Wellness Prezzi storici delle azioni Prezzo attuale dell'azione CA$0.05 Massimo di 52 settimane CA$0.15 Minimo di 52 settimane CA$0.017 Beta 1.54 1Variazione di 1 mese 127.54% Variazione a 3 mesi 102.02% Variazione di 1 anno -44.50% 3Variazione a 3 anni -91.20% Variazione a 5 anni n/a Variazione dall'IPO -93.09%
Notizie e aggiornamenti recenti
Numinus Wellness Inc. to Report Q3, 2024 Results on Jul 11, 2024 Jul 11 Numinus Wellness Inc. Appoints Jaime Gerber to Numinus Intelligence Board MedBright AI Investments Inc. (CNSX:MBAI) executed a letter of intent to acquire MedBright AI Investments Inc. (TSX:NUMI) for CAD 16.2 million in a reverse merger transaction. Jun 20
Numinus Wellness Comments on FDA Advisory Committee Meeting for Investigational MDMA-Assisted Therapy for PTSD Jun 08
Numinus Wellness Receives Health Canada Approval for Study into Group Model for MDMA-Assisted Therapy May 30
Numinus Wellness Inc. to Report Q2, 2024 Results on Apr 15, 2024 Apr 10 Vedi altri aggiornamenti
Numinus Wellness Inc. to Report Q3, 2024 Results on Jul 11, 2024 Jul 11 Numinus Wellness Inc. Appoints Jaime Gerber to Numinus Intelligence Board MedBright AI Investments Inc. (CNSX:MBAI) executed a letter of intent to acquire MedBright AI Investments Inc. (TSX:NUMI) for CAD 16.2 million in a reverse merger transaction. Jun 20
Numinus Wellness Comments on FDA Advisory Committee Meeting for Investigational MDMA-Assisted Therapy for PTSD Jun 08
Numinus Wellness Receives Health Canada Approval for Study into Group Model for MDMA-Assisted Therapy May 30
Numinus Wellness Inc. to Report Q2, 2024 Results on Apr 15, 2024 Apr 10
Numinus Wellness Inc. Submits Clinical Trial Application Mar 20
Numinus Wellness Inc., Annual General Meeting, May 21, 2024 Mar 09 Numinus Wellness Inc. has completed a Composite Units Offering in the amount of CAD 6 million. Feb 16
Numinus Wellness Inc., Annual General Meeting, Feb 26, 2024 Dec 19
Numinus Wellness Inc. to Report Q4, 2023 Results on Nov 29, 2023 Nov 22
Numinus Wellness Inc. Introduces Its Innovative and Comprehensive Psychedelic Program for Individuals Surging from Mental Distress Associated with Chronic and Serious Illness Through Cedar Clinical Research Oct 05
Numinus Wellness Inc. to Report Q3, 2023 Results on Jul 17, 2023 Jun 30
Numinus Wellness Inc. Appoints Nikhil Handa as Chief Financial Officer, Effective from June 15, 2023 Jun 15
Numinus Wellness Inc. Announces Cedar Clinical Research Jun 06
Numinus Wellness Inc. Announces to Research COMP360 Psilocybin Therapy in Treatment-Resistant Depression as Part of Large Phase 3 Study May 31
Numinus Wellness Inc Aligns Business Initiatives to Prepare for Future Approval of MDMA-Assisted Therapy May 26
Numinus Wellness Inc. Receives Clinical Trial Application Approval from Health Canada for Experiential Psychedelic-Assisted Therapy Training Using Psilocybe Cubensis Tea Feb 02
Numinus Wellness Inc. to Report Q1, 2023 Results on Jan 16, 2023 Jan 05
Numinus Wellness Inc., Annual General Meeting, Feb 15, 2023 Dec 20
Numinus Wellness Inc. Submits Clinical Trial Application to Health Canada for Experiential Psilocybin Assisted Therapy Training Research Dec 10
Numinus Wellness Inc. Reports Impairment of Good Will for the Fourth Quarter Ended August 31, 2022 Nov 30
Numinus Wellness Inc. Launches Psychedelic-Assisted Therapy for Chronic and Serious Medical Illness Oct 29
Numinus Develops Mushroom Tea for Use in Psychedelic Research Oct 06
Numinus Now Offers Ketamine-Assisted Therapy in Toronto Sep 20
Numinus Wellness Inc. to Report Q4, 2022 Results on Nov 29, 2022 Sep 14
Numinus Wellness Inc. to Report Q3, 2022 Results on Jul 14, 2022 Jul 07
Numinus Wellness Inc. Announces Launch of Pilots Mental Health Program for Corporate Clients in Utah Jun 24
Numinus Wellness Inc. Announces That Its Subsidiary Numinus Bioscience Inc Applies for International Patent Filing of Psychedelics Production Process Jun 23 Numinus Wellness Inc. (TSX:NUMI) completed the acquisition of Novamind Inc. (OTCPK:NVMD.F).
Numinus Wellness Inc. Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-assisted Therapy Treatment May 18
Numinus Announces the Music as Medicine Event Series May 02
Numinus Wellness Inc. (TSX:NUMI) entered into a definitive agreement to acquire Novamind Inc. (OTCPK:NVMD.F) for CAD 21.6 million. Apr 13
Numinus Wellness Inc. to Report Q2, 2022 Results on Apr 14, 2022 Apr 02
Numinus Wellness Inc. Completes First MDMA Administration in PTSD Trial Sponsored by MAPS Mar 31
Numinus Wellness Inc. Appoints New Bioscience Advisors to Advance IP Development Feb 02 Psilocybin and MDMA Get the Green Light for Medical Use in Canada
Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product Jan 16
Numinus Wellness Inc.(TSXV:NUMI) dropped from S&P/TSX Venture Composite Index Dec 16
Numinus Wellness Inc. (TSXV:NUMI) completed the acquisition of Neurology Centre of Toronto. Sep 24
Numinus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for Post-Traumatic Stress Disorder Jul 14
Optimi Health and Numinus Wellness Inc. Completes Pre-Clinical Trial Application Meeting Jun 16
Numinus Wellness and Optimi Health Submit All-Natural Psilocybin Extract to Health Canada for Pre-Clinical Trial Application May 12
Numinus Wellness Inc. Congratulates Multidisciplinary Association for Psychedelic Studies on Phase 3 Clinical Trial Demonstrating Significant Benefits of MDMA-Assisted Therapy for Severe PTSD May 11
Numinus Wellness Inc. has completed a Composite Units Offering in the amount of CAD 35 million. Mar 21
Numinus Wellness Inc. Receives New Amendments Under Canada's Controlled Drugs and Substances Act Enhance the Company's Ability to Lead Psychedelics Research and Support the Global Psychedelics Sector Mar 06 Optimi Health and Numinus Wellness to Conduct Psychedelic Lab Research and Development Numinus and Syreon Provide Psilocybin Compassionate Access Trial Update
Numinus Wellness Inc Announces Milestones in Compassionate Access Trial for Mdma-Assisted Therapy in Collaboration with Maps Public Benefit Corporation Feb 19
Numinus Wellness Inc. (TSXV:NUMI) completed the acquisition of Mindspace Psychology Services Inc. Feb 09
Numinus Wellness Forges Forward into Psychedelic Discovery Research with the Orbitrap Exploris 120 Mass Spectometer Jan 14
Numinus Wellness Inc. Signs Lab Services Agreement with Optimi Health Corp Jan 08
Numinus Wellness Inc. has completed a Composite Units Offering in the amount of CAD 15.00012 million. Dec 31
Numinus Wellness Inc. Completes First Extraction of its Psilocybe Mushrooms Dec 19
Numinus Wellness Inc. (TSXV:NUMI) entered into an agreement to acquire Mindspace Psychology Services Inc. Dec 17
Numinus Wellness Inc. and Multidisciplinary Association for Psychedelic Studies Public Benefit Corporation Announces Collaboration Agreement to Seek Approval of MDMA-Assisted Psychotherapy for PTSD Single-Arm, Open-Label Trial Dec 03
Numinus Announces Compassionate Access Trial of Psilocybin-Assisted Psychotherapy for Substance Use Disorders Nov 19
Numinus Wellness Inc. Appoints Multidisciplinary Global Leaders to its General Advisory Council Oct 15
Numinus Commences Psilocybe Mushroom Cultivation At Its Health Canada Licensed Laboratory Sep 26
Numinus Wellness Inc. has completed a Composite Units Offering in the amount of CAD 4 million. Sep 11 Rendimenti per gli azionisti NUMI.F US Pharmaceuticals US Mercato 7D 143.9% 1.1% 5.7% 1Y -44.5% 16.6% 36.9%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: NUMI.F ha avuto una performance inferiore rispetto al US Pharmaceuticals che ha registrato un rendimento 16.6 % nell'ultimo anno.
Rendimento vs Mercato: NUMI.F ha avuto una performance inferiore al mercato US che ha registrato un rendimento 36.9 % nell'ultimo anno.
Volatilità dei prezzi Is NUMI.F's price volatile compared to industry and market? NUMI.F volatility NUMI.F Average Weekly Movement 22.7% Pharmaceuticals Industry Average Movement 9.4% Market Average Movement 6.2% 10% most volatile stocks in US Market 15.3% 10% least volatile stocks in US Market 3.0%
Prezzo delle azioni stabile: Il prezzo delle azioni di NUMI.F è stato volatile negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale di NUMI.F è aumentata da 17% a 23% nell'ultimo anno.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 1964 n/a Payton Nyquvest www.numinus.com
Numinus Wellness Inc. fornisce prodotti e servizi di psicoterapia assistita da psichedelici in Canada e negli Stati Uniti. L'azienda opera attraverso i segmenti Clinical Research Operations, Canadian Clinic Network e U.S. Clinic Network.
Mostra di più Numinus Wellness Inc. Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Numinus Wellness con la sua capitalizzazione di mercato? NUMI.F statistiche fondamentali Capitalizzazione di mercato US$12.73m Guadagni(TTM ) -US$18.32m Ricavi(TTM ) US$16.15m
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) NUMI.F Conto economico (TTM ) Ricavi CA$22.48m Costo del fatturato CA$15.68m Profitto lordo CA$6.80m Altre spese CA$32.31m Guadagni -CA$25.51m
Ultimi guadagni dichiarati
May 31, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -0.079 Margine lordo 30.27% Margine di profitto netto -113.45% Rapporto debito/patrimonio netto 35.4%
Come si è comportato NUMI.F nel lungo periodo?
Vedi performance storica e confronto
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
